Clinical trial
Immune System Suppression With Alemtuzumab and Tacrolimus in Liver…
NCT00105235 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00105235 |
|---|---|
| Title | Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients |
| Official title | A Phase II Multicenter Trial to Assess the Safety and Efficacy of Campath-1H and Tacrolimus Followed By Immunosuppression Withdrawal in Liver Transplantation (ITN024ST) |
| Acronym | TILT |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Immune Tolerance Network (ITN) |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Liver Disease, Liver Transplantation |
| Intervention type | Drug, Procedure |
| Interventions | Alemtuzumab, Cyclosporine, Mycophenolate mofetil, Tacrolimus, Liver transplant, Immunosuppression withdrawal |
| Enrollment | 27 |
| Start date | Jun 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2011 |
| First posted | Mar 11, 2005 |
| Last update posted | Dec 27, 2012 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: